Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00005026 · ClinicalTrials.gov registry record · Phase 1
Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cancer
A Phase 1 study of Ovarian Cancer and Primary Peritoneal Cavity Cancer, sponsored by Gynecologic Oncology Group.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Study locations
NCT00005026: Completed Phase 1 study of Ovarian Cancer and Primary Peritoneal Cavity Cancer, sponsored by Gynecologic Oncology Group.
NCT00005026 is a Phase 1 study of Ovarian Cancer and Primary Peritoneal Cavity Cancer that has completed, run by Gynecologic Oncology Group. The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00005026, a Phase 1 study of Ovarian Cancer and Primary Peritoneal Cavity Cancer, has completed, sponsored by Gynecologic Oncology Group.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20
- Study locations
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of combination chemotherapy in treating patients who have stage III or stage IV ovarian epithelial or primary peritoneal cancer.
Conditions Studied
Interventions
- DRUG carboplatin
- DRUG paclitaxel
- DRUG topotecan hydrochloride
Study Locations (20)
California
- Jonsson Comprehensive Cancer Center, UCLA - Los Angeles
- Community Hospital of Los Gatos - Los Gatos
Florida
- Tampa Bay Cancer Consortium - St. Petersburg
- H. Lee Moffitt Cancer Center and Research Institute - Tampa
Illinois
- Rush-Presbyterian-St. Luke's Medical Center - Chicago
- University of Chicago Cancer Research Center - Chicago
Massachusetts
- Tufts University School of Medicine - Boston
- University of Massachusetts Memorial Medical Center - Worcester
Missouri
- Ellis Fischel Cancer Center - Columbia
- Washington University School of Medicine - St Louis
Alabama
- University of Alabama at Birmingham Comprehensive Cancer Center - Birmingham
Colorado
- University of Colorado Cancer Center - Denver
District of Columbia
- Walter Reed Army Medical Center - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Start Date | 2000-02 |
| Phase | Phase 1 |
What the finished NCT00005026 record still lists
NCT00005026 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 2 conditions, with Ovarian Cancer appearing as the primary indexed condition, and to 3 interventions - of which carboplatin is the first listed.
NCT00005026 names 20 study sites across 15 states, led by California, Florida, Illinois.
Frequently Asked Questions
What is clinical trial NCT00005026 about?
NCT00005026 is a clinical study titled "Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of combination chemotherapy in treating patients who have stage III or st...
What is the current status of trial NCT00005026?
This trial is currently completed. It is a Phase 1 study. The study started on 2000-02.
What conditions does trial NCT00005026 study?
This clinical trial studies the following conditions: Ovarian Cancer, Primary Peritoneal Cavity Cancer.
What interventions are being tested in trial NCT00005026?
The interventions under investigation include: carboplatin (DRUG), paclitaxel (DRUG), topotecan hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00005026?
This trial is sponsored by Gynecologic Oncology Group, which has 154 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00005026 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
RECRUITING · Phase 1
-
A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Bevacizumab in Adult Participants With Ovarian Cancer
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia